Balram, a senior Indian health official and chairman of the Indian Medical Research Council (ICMR), said today that the anti covid-19 oral drug produced by the US MSD group had some "major safety concerns", so the government did not include the drug in the national treatment plan. "We must remember that this drug has major safety concerns... So it is not included in the therapeutic drugs of the national task force."
In addition, Dr. reddys laboratories, an Indian pharmaceutical company, plans to launch molnupiravir, an oral drug of Merck & Co., from the beginning of next week. Molnupiravir was approved by the Ministry of health and family welfare of India on December 28.
Previously, the drug obtained the emergency use authorization of the U.S. Food and Drug Administration (FDA) on December 23 and was approved for use in high-risk patients in the United States. French health minister Welland said that due to the disappointing test data of MSD anti covid-19 oral drug, France has cancelled the order signed with the company and hopes to receive Pfizer anti covid-19 oral drug by the end of January next year.
(interface News)
